Financial Contrast: Jaguar Animal Health (JAGX) vs. OncoSec Medical (ONCS)
Jaguar Animal Health (NASDAQ: JAGX) and OncoSec Medical (NASDAQ:ONCS) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, earnings, profitability, valuation and risk.
Volatility & Risk
Jaguar Animal Health has a beta of 0.67, meaning that its share price is 33% less volatile than the S&P 500. Comparatively, OncoSec Medical has a beta of 2.52, meaning that its share price is 152% more volatile than the S&P 500.
Insider & Institutional Ownership
26.6% of Jaguar Animal Health shares are owned by institutional investors. Comparatively, 9.0% of OncoSec Medical shares are owned by institutional investors. 19.5% of Jaguar Animal Health shares are owned by insiders. Comparatively, 11.5% of OncoSec Medical shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
This is a summary of recent ratings and price targets for Jaguar Animal Health and OncoSec Medical, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Jaguar Animal Health||0||0||2||0||3.00|
Jaguar Animal Health currently has a consensus target price of $2.00, suggesting a potential upside of 412.69%. OncoSec Medical has a consensus target price of $5.33, suggesting a potential upside of 444.27%. Given OncoSec Medical’s higher possible upside, analysts plainly believe OncoSec Medical is more favorable than Jaguar Animal Health.
This table compares Jaguar Animal Health and OncoSec Medical’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Jaguar Animal Health||-757.17%||-1,693.45%||-301.91%|
Valuation & Earnings
This table compares Jaguar Animal Health and OncoSec Medical’s revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|Jaguar Animal Health||$1.79 million||23.58||-$111.45 million||($1.03)||-0.38|
|OncoSec Medical||N/A||N/A||-$21.73 million||($1.17)||-0.84|
OncoSec Medical has higher revenue, but lower earnings than Jaguar Animal Health. OncoSec Medical is trading at a lower price-to-earnings ratio than Jaguar Animal Health, indicating that it is currently the more affordable of the two stocks.
OncoSec Medical beats Jaguar Animal Health on 7 of the 11 factors compared between the two stocks.
Jaguar Animal Health Company Profile
Jaguar Health, Inc., formerly Jaguar Animal Health, Inc., is a natural-products pharmaceuticals company. The Company is focused on developing and commercializing novel, sustainably derived gastrointestinal products for both human prescription use and animals on a global basis. The Company, through its subsidiary Napo Pharmaceuticals, Inc., is focused on developing and commercializing proprietary human gastrointestinal pharmaceuticals for the global marketplace from plants used traditionally in rainforest areas. Its Mytesi is an antidiarrheal indicated for the symptomatic relief of noninfectious diarrhea in adult patients with human immunodeficiency virus HIV/ acquired immune deficiency syndrome (AIDS) on antiretroviral therapy. Its other products include Canalevia, Equilevia, Neonorm Calf and Neonorm Foal.
OncoSec Medical Company Profile
OncoSec Medical Incorporated is a biotechnology company. The Company is focused on designing, developing and commercializing gene therapies, therapeutics and medical approaches to stimulate an anti-tumor immune response for the treatment of cancer. The Company’s lead product candidate, ImmunoPulse IL-12, consists of a plasmid construct encoding the proinflammatory cytokine, IL-12, which is delivered into the tumor through in vivo electroporation. As of July 31, 2016, the Company was pursuing two Phase II trials: ImmunoPulse IL-12 monotherapy in patients with metastatic melanoma and ImmunoPulse IL-12 plus pembrolizumab in patients with advanced, metastatic melanoma. In addition, it is pursuing ImmunoPulse IL-12 monotherapy in patients with triple negative breast cancer. Its ImmunoPulse product candidates are based on its deoxyribonucleic acid (DNA)-based immunotherapy technology, which is designed to stimulate the human immune system, resulting in systemic anti-tumor immune responses.
Receive News & Stock Ratings for Jaguar Animal Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jaguar Animal Health Inc. and related stocks with our FREE daily email newsletter.